A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination with Nivolumab in Subjects with Selected Advanced Solid Tumors or Hematologic Malignancies

Trial Profile

A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination with Nivolumab in Subjects with Selected Advanced Solid Tumors or Hematologic Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs BMS 986158 (Primary)
  • Indications Breast cancer; Ovarian cancer; Small cell lung cancer
  • Focus Adverse reactions; First in man
  • Acronyms BET
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 18 Apr 2016 The number of treatment arms have been reduced from 8 to 6. Hence the patient no. has also been reduced.
    • 18 Apr 2016 Planned number of patients changed from 185 to 150.
    • 03 Sep 2015 Planned End Date changed from 1 Jul 2020 to 1 Dec 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top